Edition:
United States

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

4.45USD
2:29pm EST
Change (% chg)

$0.05 (+1.14%)
Prev Close
$4.40
Open
$4.35
Day's High
$4.50
Day's Low
$4.35
Volume
64,108
Avg. Vol
92,075
52-wk High
$6.45
52-wk Low
$2.58

Latest Key Developments (Source: Significant Developments)

Adamis Pharmaceuticals Announces Submission Of Investigational New Drug (Ind) Application To The FDA
Monday, 4 Dec 2017 04:05pm EST 

Dec 4 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE FDA FOR NEW PRODUCT CANDIDATE FOR THE TREATMENT OF OPIOID OVERDOSE.  Full Article

Adamis Pharma Submits Prior Approval Supplement To FDA For The Pediatric Version Of Symjepi
Wednesday, 29 Nov 2017 04:05pm EST 

Nov 29 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS SUBMITS PRIOR APPROVAL SUPPLEMENT TO FDA FOR THE PEDIATRIC VERSION OF SYMJEPI.ADAMIS PHARMACEUTICALS CORP - SUBMISSION OF A PRIOR APPROVAL SUPPLEMENT TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDIATRIC VERSION (0.15MG) OF SYMJEPI.  Full Article

Adamis Pharmaceuticals gets FDA approval for co's epinephrine pre-filled syringe
Thursday, 15 Jun 2017 02:31pm EDT 

June 15 (Reuters) - Adamis Pharmaceuticals Corp ::Adamis pharmaceuticals receives FDA approval for its epinephrine pre-filled syringe.Adamis pharmaceuticals receives FDA approval for its epinephrine pre-filled syringe.FDA has also approved PFS trade name of Symjepi.‍FDA approved Adamis' epinephrine injection, USP, 1:1000 for emergency treatment of allergic reactions including anaphylaxis​.Are preparing to submit second NDA for junior version of Symjepi to FDA.Expect to build inventory levels in preparation for anticipated launch in H2 of year for co's epinephrine pre-filled syringe.  Full Article

Perceptive Advisors reports 5.57 pct stake in Adamis Pharma
Monday, 24 Apr 2017 09:21am EDT 

April 24 (Reuters) - Adamis Pharmaceuticals Corp ::Perceptive Advisors LLC reports 5.57 percent passive stake in Adamis Pharmaceuticals Corp as of April 21 - SEC filing.  Full Article

Adamis Pharmaceuticals announces pricing of public offering of common stock
Friday, 21 Apr 2017 09:13am EDT 

April 21 (Reuters) - Adamis Pharmaceuticals Corp :Adamis Pharmaceuticals announces pricing of public offering of common stock.Says public offering of 4.29 million common shares priced at $3.50per share.Adamis Pharmaceuticals Corp - Offering is expected to close on April 26, 2017.  Full Article

Adamis Pharmaceuticals announces proposed public offering of common stock
Thursday, 20 Apr 2017 04:01pm EDT 

April 20 (Reuters) - Adamis Pharmaceuticals Corp -:Adamis Pharmaceuticals announces proposed public offering of common stock.Adamis Pharmaceuticals -intends to use net proceeds for general corporate purposes, which may includeexpenditures relating to research, among others.  Full Article

Sabby Management, LLC reports 7.73 pct passive stake in Adamis Pharmaceuticals
Tuesday, 9 Aug 2016 03:29pm EDT 

Adamis Pharmaceuticals Corp : Sabby Management, LLC reports 7.73 pct passive stake in Adamis Pharmaceuticals as of August 3, 2016 - SEC Filing Source - http://bit.ly/2aJYpKi Further company coverage: [ADMP.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

CVI Investments reports 5.5 pct passive stake in Adamis Pharmaceuticals
Monday, 8 Aug 2016 01:30pm EDT 

:CVI Investments Inc reports a passive stake of 5.5 percent in Adamis Pharmaceuticals Corp as of July 29, 2016 - SEC Filing.  Full Article

Adamis Pharmaceuticals announces $11.1 mln offering
Friday, 29 Jul 2016 08:45am EDT 

Adamis Pharmaceuticals Corp : Adamis Pharmaceuticals announces $11.1 million registered direct offering . Estimates that net offering proceeds, after deducting placement agent fees, will be approximately $10.3 million .Adamis Pharmaceuticals Corp says offering was priced at $3.095 per unit.  Full Article

Adamis Pharmaceuticals- private placement of about $5 mln
Tuesday, 12 Jul 2016 09:00am EDT 

Adamis Pharmaceuticals Corp : Adamis Pharmaceuticals announces private placement . Says received gross cash proceeds of approximately $5 million .Says issued 1.7 million shares of series A-2 convertible preferred stock to a small number of institutional investors.  Full Article

BRIEF-Adamis Pharmaceuticals Subsidiary Develops Compound To Manage Ulcers In Horses

* US COMPOUNDING, A SUBSIDIARY OF ADAMIS PHARMACEUTICALS, DEVELOPS A UNIQUE COMPOUND TO MANAGE ULCERS IN HORSES Source text for Eikon: Further company coverage: